Eli Lilly announced the launch of Trulicity (dulaglutide) pen indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Trulicity pen is intended for once-weekly dosing and does not require the patient to mix, measure, or handle the needle. It contains dulaglutide, a glucagon-like peptide-1 receptor agonist, which increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.
RELATED: Trulicity Pen Approved for Type 2 Diabetes
Trulicity is available as 0.75 and 1.5mg single-use pens in 4-count cartons.
For more information call (800) 545-5979 or visit Trulicity.com.